[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"genetics\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:genetics":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,49,74,108,141,168,194,219,294,320,343],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100652303","multimodal-biomarkers-in-coronary-artery-disease-pathogenesis-the-oxford-acute-myocardial-infarction-study-oxami-study-100652303",false,"NCT07772570","Multimodal Biomarkers in Coronary Artery Disease Pathogenesis: The Oxford Acute Myocardial Infarction Study (OXAMI Study)","OXAMI","Inclusion Criteria:\n\n* Evidence of myocardial injury (e.g. elevation of troponin or other cardiac biomarkers, ECG changes, wall motion abnormalities on cardiac imaging) AND\u002FOR referred for coronary angiography with view to proceed to PCI as indicated in either non-emergency or emergency settings.\n\nExclusion Criteria:\n\n* Patients in whom safety or clinical concerns preclude participation.\n* Anaemia (Hb \\\u003C9).\n* Pregnant or breast feeding females.\n\nAdditional exclusion criteria for patients undergoing MRI\n\n* claustrophobia which limits \u002F prevents participants from remaining in MRI scanner.\n* patients who cannot lie flat on the scan table.\n* patients with metallic implants, pacemakers, implantable defibrillators etc, unless known to be MRI compatible.\n* patients with known allergy to medium of contrast (gadolinium)\n\nAdditional exclusion criteria for patients undergoing coronary CT angiography\n\n* patients with a known allergy to iodinated contrast media\n* eGFR\\\u003C 30 ml\u002Fmin (stage 3-5 renal disease)",true,"ALL","18 Years","90 Years",{"count":21,"type":22},2000,"ESTIMATED","20 Years","OBSERVATIONAL","Coronary artery disease is one of the most common causes of illness and death. It develops when fatty deposits, known as plaques, build up in the arteries that supply blood to the heart. These plaques can gradually narrow the arteries and reduce blood flow, causing symptoms such as chest pain (angina). Sometimes a plaque can suddenly break open, causing a blood clot to form and block the artery. This can lead to a heart attack and permanent damage to the heart muscle.\n\nAlthough much has been learned about coronary artery disease, important questions remain about why some plaques suddenly become unstable, how this affects blood flow through the smallest blood vessels of the heart, and why some patients develop more heart muscle damage than others.\n\nThe Oxford Acute Myocardial Infarction (OxAMI) research programme aims to improve our understanding of these processes. We will study both the disease within the coronary arteries (the \"upstream\" problem) and its effects on the heart muscle (the \"downstream\" damage). By examining these together, we hope to understand more clearly how changes in coronary plaques lead to heart injury and how this differs between patients.\n\nPatients undergoing procedures to investigate or treat coronary artery disease provide an important opportunity to study these processes. During coronary angioplasty (also called percutaneous coronary intervention or PCI), a narrow or blocked artery is opened, usually using a small balloon and a stent. This procedure can disturb the underlying plaque in a similar way to the plaque disruption that occurs during a heart attack. Where appropriate, we may therefore collect blood and material released from the plaque during these procedures. Blood may be collected from different locations in the circulation, allowing us to study substances released by the plaque and heart muscle. Material that would otherwise be discarded during treatment may also be collected for laboratory analysis.\n\nWe will use several established and newer techniques to examine the coronary arteries, the small blood vessels within the heart, and the heart muscle. These may include detailed imaging from inside the coronary arteries using intravascular ultrasound (IVUS) or optical coherence tomography (OCT). We may also measure blood pressure and flow within the coronary arteries to assess how well the small blood vessels supplying the heart are working.\n\nNon-invasive heart scans may include cardiovascular magnetic resonance (CMR\u002FMRI), cardiac computed tomography (CT) and echocardiography (ultrasound). These techniques can provide detailed information about the structure and function of the heart, blood supply to the heart muscle, areas of injury or permanent scarring, and changes that occur following a heart attack. In particular, MRI may help distinguish heart muscle that has been permanently damaged from muscle that is injured but could potentially recover after blood flow is restored. This may be especially important for patients who arrive at hospital several hours after their heart attack began.\n\nOther measurements may include electrocardiograms (ECGs), which record the electrical activity of the heart, and measurements of heart pressure, volume and function. Some participants may also have longer-term ECG monitoring.\n\nBlood and tissue samples may be analysed using a range of laboratory techniques. These studies will investigate inflammation, blood clotting and other biological processes involved in coronary artery disease and heart attacks. Newer laboratory methods may allow us to measure large numbers of proteins and small molecules in the blood. Material collected from plaques may also be examined under a microscope to identify its cells and structural components.\n\nWith additional consent, blood samples may be stored for genetic research. This could help us understand whether differences in people's genes influence their risk of coronary artery disease, their response to a heart attack, or the amount of heart damage that occurs.\n\nBy combining information about coronary plaques, blood flow through the heart's circulation, heart muscle injury, imaging, blood and tissue markers, and genetic factors, OxAMI aims to build a detailed picture of coronary artery disease and heart attacks. The programme will establish a carefully characterised group of research participants who may contribute to future OxAMI studies conducted under separate research protocols.\n\nUltimately, this research aims to identify better ways to predict, diagnose and understand coronary artery disease and heart attacks, and to identify new approaches that could improve treatment and outcomes for future patients.",[27,28,29,30,31,32,33,34,35],"Myocardial Injury","Atherosclerosis Cardiovascular Disease","Cardiac Imaging Techniques","Genetics","Thrombus","Trained Immunity","Biomarker Discovery","Coronary Physiology","Intravascular Imaging and Microvascular Obstruction","RECRUITING","2026-08-14",{"date":39,"type":40},"2026-08-19","ACTUAL",{"date":42,"type":40},"2012-05",{"date":44,"type":22},"2046-12",{"name":46,"class":47},"University of Oxford","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":58,"conditions":59,"keywords":4,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":4},"100645545","abcg8-ugt1a1-and-gallstone-disease-after-bariatric-surgery-100645545","NCT07702630","ABCG8, UGT1A1 and Gallstone Disease After Bariatric Surgery","ABCG8, UGT1A1 and Gallstone Disease After Bariatric Surgery: A Genetic Study","Inclusion Criteria:\n\n* Bariatric surgery\n\nExclusion Criteria:\n\n* Gallstone disease or cholecystectomy prior to bariatric surgery",{"count":57,"type":22},270,"The goal of this observational genetic case-control study is to learn whether two specific genetic variants in ABCG8 and UGT1A1 are associated with gallstone disease after bariatric surgery. The study includes adults who have previously undergone bariatric surgery.\n\nThe main questions it aims to answer are whether the ABCG8 D19H variant and the UGT1A1 rs6742078 variant are associated with an increased risk of gallstone disease requiring cholecystectomy after bariatric surgery.\n\nResearchers will compare patients who underwent bariatric surgery and later had their gallbladder removed because of gallstone disease with patients who underwent bariatric surgery but did not develop gallstone disease or undergo cholecystectomy during follow-up.\n\nParticipants will provide one blood sample for targeted genetic analysis and complete questionnaires about health, previous surgery, medication use, family history, and gastrointestinal quality of life. Relevant clinical information will also be collected from medical records.",[60,61,62,63,30],"Gallstone Disease","Bariatric Surgery","Metabolic Surgery","Cholecystectomy","NOT_YET_RECRUITING","2026-07-16",{"date":67,"type":40},"2026-07-17",{"date":69,"type":22},"2026-10-01",{"date":71,"type":22},"2029-03-01",{"name":73,"class":47},"Esbjerg Hospital - University Hospital of Southern Denmark",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":83,"conditions":84,"keywords":90,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":98,"lastUpdatePostDateStruct":99,"startDateStruct":101,"completionDateStruct":103,"leadSponsor":105,"locationsCount":107},"100504659","mechanisms-of-disease-progression-in-aortic-stenosis---the-modas-study-100504659","NCT05851209","Mechanisms Of Disease Progression in Aortic Stenosis - the MODAS Study","Evaluation of Immunologic and Image Morphologic Parameters to Predict Disease Progression in Patients With Moderate Aortic Valve Stenosis","Inclusion Criteria:\n\n* The patient has an acquired (tricuspid) moderate aortic valve stenosis, which is the reason for regular outpatient cardiological care.\n* The subject has been informed verbally and in writing about the study and has given written consent to participate in this study.\n* Age \\> 18 years\n\nExclusion Criteria:\n\n* The subject has contraindications for the performance of a magnetic resonance imaging or computed tomography (e.g., severe arrhythmias , contrast agent intolerance, a pacemaker, or severe renal insufficiency or severe renal insufficiency or claustrophobia).\n* Presence of only mild or already high-grade acquired tricuspid Aortic valve stenosis\n* Patient with bicuspid aortic valve\n* Inability to follow the instructions of study personnel\n* Lack of written informed consent",{"count":82,"type":22},938,"Biomarkers and mechanisms in the progression of aortic valve stenosis are sometimes not sufficiently understood. The current project will take into account image morphological and immunological aspects that predict the development of hemodynamically relevant aortic valve stenosis in order to identify high-risk patients and to develop further therapeutic options.",[85,86,87,88,89,30],"Aortic Stenosis","Imaging","Pathogenesis","Disease Progression","Aortic Valve Calcification",[91,92,93,94,95,96,97],"severe aortic stenosis","disease progression","pathogenesis of degenerative aortic stenosis","early detection","Cardiovascular magnet resonance","Transthoracal echocardiography","computertomography","2026-06-26",{"date":100,"type":40},"2026-06-30",{"date":102,"type":40},"2023-07-01",{"date":104,"type":22},"2031-07",{"name":106,"class":47},"Heinrich-Heine University, Duesseldorf",3,{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":116,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":119,"conditions":120,"keywords":123,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100641833","genetic-microbiological-and-behavioral-factors-in-obesity-100641833","NCT07650149","Genetic, Microbiological and Behavioral Factors in Obesity","OPTIMIZE GEN - Outcomes of Persistence and Treatment With tIrzepatide deterMined by Genetic, mIcrobiological & bEhavioral Factors in obEsity","OPTIMIZE-GEN","Inclusion criteria\n\n* Age 18-60 years\n* Consent to participate in the study and providing informed written consent\n* Overweight or obese with a BMI \\>27\n\nExclusion criteria\n\n* Contraindications to tirzepatide use:\n* Type 1 or type 2 diabetes\n* Pregnancy or breastfeeding\n* Cancer\n* Heart failure\n* Expected lack of patient compliance\n* Taking immunosuppressive medications, steroids, NSAIDs, antibiotics (within 2 weeks prior to sample collection),\n* Autoimmune and inflammatory diseases, acute infectious diseases, AIDS, tuberculosis\n* Mental illness\n* Alcohol dependence syndrome\n* Liver cirrhosis\n* Post-myocardial infarction or stroke","60 Years",{"count":118,"type":22},200,"This study will assess the impact of genetic markers, microbiological (microbiome) and behavioral factors on tolerance, adherence and effectiveness of dual GLP1\u002FGIP RA in the treatment of obesity.\n\n200 consecutive patients who meet all inclusion and none of the exclusion criteria will be enrolled.",[121,122,30],"Obesity & Overweight","Obesity",[124,125,126,127,128,129,130],"tirzepatide","obesity","genetics","microbiom","adherence","compliance","gene","2026-06-15",{"date":133,"type":40},"2026-06-16",{"date":135,"type":40},"2026-05-23",{"date":137,"type":22},"2028-05",{"name":139,"class":47},"Jan Kochanowski University",2,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":150,"phases":151,"briefSummary":153,"conditions":154,"keywords":157,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":48},"100628298","genomic-of-congenital-sideroblastic-anemias-100628298","NCT07459816","Genomic of CONgenital Sideroblastic Anemias","GASCON-2","Inclusion Criteria:\n\n* Patient with unexplained congenital sideroblastic anemia on the molecular side with the gene panels used routinely\n* Patients already identified by exome sequencing approach carrying bi-allelic variants of candidate genes of the mitochondrial respiratory pathway.\n* Patients meeting the same criteria who will be identified prospectively over the next 12 months\n\nExclusion Criteria:\n\n* NA",{"count":149,"type":22},20,"INTERVENTIONAL",[152],"NA","Congenital sideroblastic anemias (CSA) are a group of rare disorders characterized by abnormal iron utilization during erythropoiesis, leading to mitochondrial iron overload, the formation of ring sideroblasts, and ineffective erythropoiesis resulting in anemia. Ring sideroblasts are erythroid precursors that contain non-heme iron deposits in their mitochondria, forming a distinctive ring-like pattern around the nucleus. Mitochondria are double membrane organelle provide a large amount of energy for cellular activities, by the process of oxidative phosphorylation (OXPHOS). The role of mitochondria has been well described in erythropoiesis. CSA exhibits clinical heterogeneity, affecting only the erythroid system in some cases, while in others presenting as part of broader syndromic conditions. Their molecular basis remains imperfectly known, although the development of next- generation sequencing technology brought tremendous advances in the understanding of their genetic features. More than 20 genes have been identified as causative of CSA, with all modes of inheritance observed: X-linked recessive, autosomal dominant, autosomal recessive, pseudo- dominant, and mitochondrial. These genes are typically involved in one of four key mitochondrial pathways: i) Heme biosynthesis (e.g., ALAS2, SLC25A38); ii) Iron-sulfur cluster biosynthesis and transport (e.g., GLRX5, HSPA9, HSCB); iii) tRNA synthesis and maturation (e.g., PUS1, YARS2, LARS2, IARS2, SARS2, MARS1, TRNT1); iv) Mitochondrial respiratory chain synthesis (e.g., NDUFB11).\n\nHowever, in nearly 30% of cases within the French CSA cohort, the underlying genetic cause remains unknown. In these patients with molecularly unexplained whole genome or exome sequencing approaches focusing on genes involved in mitochondrial function and iron metabolism identified several possibly pathogenic variants in CSA patients. These genes were not clearly described as playing a role in erythropoiesis or heme or iron metabolism. We hope to confirm their role in CSA. However, in nearly 30% of cases within the French CSA cohort , the underlying genetic cause remains unknown. The investigators hope to confirm the role in CSA of gene identified with exome sequencing approaches.",[155,30,156],"Anemia","Erythropoiesis",[155,126,158],"erythropoiesis","2026-03-09",{"date":161,"type":40},"2026-03-11",{"date":163,"type":40},"2025-10-28",{"date":165,"type":22},"2026-11",{"name":167,"class":47},"Centre Hospitalier Universitaire, Amiens",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":16,"sex":17,"minAge":23,"maxAge":176,"enrollmentInfo":177,"targetDuration":4,"studyType":150,"phases":179,"briefSummary":180,"conditions":181,"keywords":182,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":48},"100626070","inherited-and-environmental-risks-acting-on-body-weight-100626070","NCT07430852","Inherited and Environmental Risks Acting on Body Weight","Genetic and Environmental Contributions to Obesity Pathogenesis","INTERACT","Inclusion Criteria:\n\n* Age 20-45 years\n* Differs in habitual diet from co-twin (study 1).\n* Willing to undergo 7-day overfeeding and hypocaloric feeding periods (study 2)\n* Member of the Washington State Twin Registry\n\nExclusion Criteria:\n\n* History of bariatric surgery or active participation in weight-loss program\n* Major medical or neurological disorder (e.g., diabetes, multiple sclerosis)\n* Known gallbladder disease, anemia, impaired thyroid, kidney or liver function or hypertriglyceridemia (\\>350 mg\u002Fdl) (study 2)\n* Current use of weight-loss medications or other medications known to alter appetite (e.g., atypical anti-psychotics)\n* High levels of vigorous physical activity (\\>300 min.\u002Fweek)\n* Pregnancy, menopause, or breastfeeding\n* Individuals with severe food allergies and dietary restrictions (e.g., vegan\u002Fvegetarian, gluten-free, others) (study 2)\n* Co-twin unwilling or unable to participate\n* MRI contraindication (e.g., implanted metal, claustrophobia)\n* Lifetime eating disorder\n* Current smoking or heavy alcohol use (≥ 2 drinks per day for females and ≥ 3 drinks per day for males)\n* BMI \\> 45 kg\u002Fm2 (study 1)\n* BMI \\> 35 kg\u002Fm2 (study 2)\n* Weight \\> 350 pounds or determined to be safe by MRI tech (MRI limit)\n* Inability to participate in a controlled diet program (study 2) or undergo other study procedures\n* Non-English speaking-or-reading individuals","45 Years",{"count":178,"type":22},110,[152],"The goal of this research is to investigate genetic and environmental factors that contribute to obesity through brain inflammation. The main questions are 1) if identical twins, who differ in food consumption habits, have differences in adiposity markers and brain inflammation and 2) if signs of brain inflammation in response to a specific diet is modified by genetics.",[30,122],[183,184],"Gliosis","Eating patterns","2026-02-18",{"date":187,"type":40},"2026-02-24",{"date":189,"type":22},"2026-09-01",{"date":191,"type":22},"2030-04-30",{"name":193,"class":47},"University of Washington",{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":16,"sex":17,"minAge":201,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":150,"phases":205,"briefSummary":206,"conditions":207,"keywords":209,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":211,"lastUpdatePostDateStruct":212,"startDateStruct":214,"completionDateStruct":216,"leadSponsor":217,"locationsCount":140},"100364392","phenotyping-genetic-risk-for-type-2-diabetes-100364392","NCT04024631","Phenotyping Genetic Risk for Type 2 Diabetes","Phenotyping Children and Adults With Possible High or Low Genetic Risk for Type 2 Diabetes","Inclusion Criteria:\n\n* Age 10-70 years\n* Prior participant of the UPenn Biobank or Center for Applied Genomics Biobank and agreed to be recontacted for future research.\n* Adults with BMI 25kg\u002Fm2 or higher, children and adolescents with BMI 85th percentile or higher\n\nExclusion Criteria:\n\n* prior diagnosis of type 1, type 2, or secondary diabetes\n* use of medications that would impact glucose and insulin response such as steroids, metformin or other anti-diabetic medication\n* acute illness that may impact insulin and glucose dynamics\n* pregnancy\n* hypothalamic obesity or related genetic disorder of metabolism\n* recent systemic chemotherapy use\n* gastrointestinal impairment or surgery that may impact absorption\n* anemia\n* major organ system illness or any underlying condition requiring regular medication or treatment that could make implementation of the protocol or interpretation of the study results difficult\n* inability to comply with study protocol","10 Years","70 Years",{"count":204,"type":22},100,[152],"This study tests the hypothesis that non-diabetic individuals with a high genetic risk score for type 2 diabetes have impaired glucose tolerance and insulin resistance compared to those with a low genetic risk score for type 2 diabetes.",[208,30],"Diabetes Mellitus, Type 2",[210],"polygenic risk for type 2 diabetes","2025-09-03",{"date":213,"type":40},"2025-09-10",{"date":215,"type":40},"2019-06-17",{"date":100,"type":22},{"name":218,"class":47},"University of Pennsylvania",{"id":220,"slug":221,"hasResults":11,"nctId":222,"briefTitle":223,"officialTitle":224,"acronym":225,"eligibilityCriteria":226,"healthyVolunteers":16,"sex":17,"minAge":227,"maxAge":4,"enrollmentInfo":228,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":230,"conditions":231,"keywords":255,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":48},"100469557","generation-victoria-cohort-2020s-a-statewide-longitudinal-cohort-study-of-victorian-children-and-their-parents-100469557","NCT05394363","Generation Victoria Cohort 2020s: A Statewide Longitudinal Cohort Study of Victorian Children and Their Parents","Generation Victoria Cohort 2020s. A Statewide Longitudinal Cohort of Victorian Children and Their Parents","GenV","Inclusion Criteria (Children):\n\n* Birth date between 4th October 2021 and 3rd October 2023\n* Live at the time of recruitment\n* Residing in Victoria at the time of recruitment\n* Has a legally acceptable representative capable of understanding the informed consent document and providing consent on the child's behalf, who provides a signed and dated informed consent form (e.g. a parent\u002Fguardian)\n\nInclusion Criteria (Adults):\n\n* Be a parent or guardian of a child who meets the eligibility criteria above\n* Provide a signed and dated informed consent form or have a legally acceptable representative capable of understanding the informed consent document and providing consent on the participant's behalf.\n\nExclusion criteria:\n\n* Children who are deceased at the time of recruitment (i.e. still born or died after birth) and their parents\u002Fguardians\n* Families unable to provide informed consent in any of the languages available","1 Day",{"count":229,"type":22},150000,"Generation Victoria (GenV) is a longitudinal, population-based study of Victorian children and their parents that will bring together data on a wide range of conditions ,exposures and outcomes. GenV blends study-collected, study-enhanced and linked data. It will be multi-purpose, supporting observational, interventional, health services and policy research within the same cohort. It is designed to address physical, mental and social issues experienced during childhood, as well as the antecedents of a wide range of diseases of ageing. It seeks to generate translatable evidence (prediction, prevention, treatments, services) to improve future wellbeing and reduce the future disease burden of children and adults.\n\nThe GenV Cohort 2020s is open to all children born over a two-year period, and their parents, residing in the state of Victoria Australia. The GenV Cohort 2020s is preceded by an Advance Cohort of children born between 5 Dec 2020 and 3 October 2021, and their parents. This comprises all families recruited at GenV's Vanguard hospital (Joan Kirner Women's and Children's) and at birthing hospitals throughout Victoria as GenV scaled up to commence recruiting for the GenV Cohort 2020s. The Advance Cohort have ongoing and full participation in GenV for their lifetime unless they withdraw but may have less complete data and biosamples.",[232,233,234,235,236,237,238,239,240,241,30,242,243,244,245,246,247,248,249,250,251,122,252,253,254],"Mental Health","Child Wellbeing","Infant Health","Child Health","Reproductive Health","Healthy Aging","Health Equity","Quality of Life","Social Determinants of Health","Environmental Exposure","Cognition","Learning","Child Development","Congenital Abnormalities","Disability","Injuries","Communicable Diseases","Noncommunicable Diseases","Physical Fitness","Diet","Allergy and Immunology","Inflammation","Intergenerational Relations",[256,225,257,258,259,235,260,261,262,263,264,265,266,267,268,269,270,271,272,273,274,275,238,276,277,278,279,280,281,282,240,283,284],"Generation Victoria","Cohort Studies","Data Collection","Data Linkage","Midlife Health","Children","Infants","Family","Parents","Mothers","Fathers","Life course perspective","Population Health","Longitudinal Studies","Genetics, population","Demography","Epidemiology","Health Disparity","Minority Health","Vulnerable Populations","Clinical Trial","Randomized Controlled Trial","Pragmatic Clinical Trial","Health Services Research","Economic Models","Value of Life","Geographic Information Systems","Climate Change","Built Environment","2025-07-30",{"date":287,"type":40},"2025-08-03",{"date":289,"type":40},"2021-10-04",{"date":291,"type":22},"2033-10",{"name":293,"class":47},"Murdoch Childrens Research Institute",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":4,"eligibilityCriteria":300,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":301,"targetDuration":303,"studyType":24,"phases":4,"briefSummary":304,"conditions":305,"keywords":309,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":311,"lastUpdatePostDateStruct":312,"startDateStruct":314,"completionDateStruct":316,"leadSponsor":318,"locationsCount":48},"100579570","trectamu-cancer-prevention-registry-and-repository-100579570","NCT06826014","TREC@TAMU Cancer Prevention Registry and Repository","Texas Regional Excellence in Cancer (TREC) @Texas A&M University Cancer Prevention Registry and Repository","Inclusion Criteria:\n\n* 18 years of age and older, and,\n* People participating in the Cancer Prevention and Research Institute of Texas (CPRIT) A coordinated cancer screening research program in Bryan and Navasota Family Medicine Clinics and,\n* People with COPD, liver disease, cervical intraepithelial neoplasia (CIN) lesions, having had a colonoscopy or a low dose computed tomography (LDCT) lung scan or cervical exam in the last 12 months or scheduled for one, and,\n* Able to give and comprehend the consent process, and,\n* Able to consent to donate blood and urine samples, genetic material through buccal swabs for future research, and,\n* Able to understand that their specimens, health record, and changes in health status will be followed for a five-year period and shared in deidentified form with the research community, and,\n* All sexes and gender identities.\n\nExclusion Criteria:\n\n* Declines to participate or interact with staff\u002Fshare their medical status.\n* A diagnosis of Alzheimer's disease or related dementias in a medical record indicates a progressive, debilitating condition that impairs memory, thought processes, and functioning Individuals who are unable or unwilling to provide consent will be excluded",{"count":302,"type":22},2500,"5 Years","This study collects health and genetic information to implement cancer prevention and treatment strategies.",[306,30,307,251,308],"Cancer","Disease","Lifestyle Factors",[310,126],"cancer","2025-02-11",{"date":313,"type":40},"2025-02-13",{"date":315,"type":22},"2025-03",{"date":317,"type":22},"2030-11",{"name":319,"class":47},"Texas A&M University",{"id":321,"slug":322,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":325,"acronym":326,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":330,"conditions":331,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":334,"lastUpdatePostDateStruct":335,"startDateStruct":337,"completionDateStruct":339,"leadSponsor":341,"locationsCount":140},"100570962","cardiometabolic-risk-of-obese-subjects-cross-sectional-study-100570962","NCT06714058","Cardiometabolic Risk of Obese Subjects: Cross-sectional Study","Cardiometabolic Risk of Obese Subjects: Cross-sectional Study for the Identification of Genetic, Laboratory and Clinical Determinants","MiRNome","Inclusion Criteria:\n\n* • Age \\> 18 years\n\n  * BMI \\> 30 Kg\u002Fm2\n  * In primary prevention for cardiovascular disease\n  * Ability to communicate, make themselves understood and adhere to study-specific procedures\n  * Willingness to participate in the study and obtain informed consent\n\nExclusion Criteria:\n\n* Patients already enrolled by the Research Units involved in the enrolment\n* Glycated hemoglobin level \\> 55 mmol\u002FL\n* Patients suffering from obesity secondary to endocrinological diseases or iatrogenic causes\n* Patients with heterozygous Familial Hypercholesterolemia (Dutch Lipid Score - DLS\\>8)\n* Patients suffering from hypercholesterolemia secondary to lipid or iatrogenic extra-metabolic pathologies\n* Patients suffering from systemic inflammatory or oncological diseases\n* Patients on active treatment with GLP-1 analogues\n* Pregnancy and breastfeeding\n* Any medical or surgical condition that makes the patient's adherence to the study protocol complex or inconsistent.",{"count":329,"type":22},240,"experimental study with analysis on tissues. This study aims to study cardiometabolic risk from a genetic, clinical, instrumental and laboratory point of view in a population of subjects with obesity.",[332,333,30],"Obesity and Obesity-related Medical Conditions","Cardiovascular Risk","2024-12-03",{"date":336,"type":40},"2024-12-05",{"date":338,"type":22},"2024-11-30",{"date":340,"type":22},"2025-04-30",{"name":342,"class":47},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":344,"slug":345,"hasResults":11,"nctId":346,"briefTitle":347,"officialTitle":348,"acronym":349,"eligibilityCriteria":350,"healthyVolunteers":16,"sex":17,"minAge":4,"maxAge":18,"enrollmentInfo":351,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":353,"conditions":354,"keywords":359,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":48},"100335700","ivf-offspring-born-in-guangzhou-100335700","NCT03650829","IVF Offspring Born in Guangzhou","IVF Offspring Born in Guangzhou Cohort Study","IVF-BIG","Inclusion Criteria:\n\n* Pregnant women with \\\u003C20 weeks of gestation\n* Pregnant women intended to eventually deliver in Guangzhou Women and Children's Medical Center\n* Permanent residents or families intended to remain in Guangzhou with their child for ≥3 years\n* Pregnant women conceived by assited reproductive technology\n\nExclusion Criteria:\n\n• None",{"count":352,"type":22},3000,"The IVF Offspring Born in Guangzhou Cohort Study (IVF-BIG) was established to investigate the short- and long-term effects of exposure in early life on the health of mothers and offspring in Guangzhou, China. Data are collected regarding assisted reproductive technology (ART), environmental, occupational and lifestyle exposures as well as health outcomes in their later life. Biological samples including blood and tissue samples are also collected from participants.",[355,356,30,357,358],"ART","Offspring, Adult","Host and Microbiome","Neurodevelopment",[355,360,361,362],"Offspring","Development","Cohort","2024-02-22",{"date":365,"type":40},"2024-02-26",{"date":367,"type":40},"2012-02-01",{"date":369,"type":22},"2038-12-31",{"name":371,"class":47},"Guangzhou Women and Children's Medical Center"]